Studies on cannabidiol (CBD)

Both positive and negative studies will be listed here. Known negative studies will be in red so you can judge for yourself whether it was rational science, or just "pot hysteria". CBD acts mostly as an anti-inflammatory and chemical moderator.

This page will be updated here and there as I have time to enter more studies. If you have a study you want listed here, please provide at least a link to the study in the comments. If you can't find a link to a free full study, a link to an abstract is fine. 

Number of studies on this page: 13

Alzheimer's
See Neurological Disorders.

Anti-inflammation and anti-oxidation

1. Booz, G. W. (2011). Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress. Free Radical Biology & Medicine, 51(5), 1054–1061. http://doi.org/10.1016/j.freeradbiomed.2011.01.007. Link to NIH abstract. Full EPUB and PDF also available. 
2. Klein TW, Newton CA. Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol. 2007;601:395-413. Review. PubMed PMID: 17713029. "...preclinical data with cannabinoid-based drugs suggest efficacy in other inflammatory diseases such as inflammatory bowel disease, Alzheimer's disease, atherosclerosis, and osteoporosis." Link to NIH abstract.

Dementia
See Neurological Disorders.


Diabetes and related complications

1. Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2012). The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications. The American Journal of Pathology, 180(2), 432–442. http://doi.org/10.1016/j.ajpath.2011.11.003. "...experimental evidence and clinical trials have clearly shown that ECS plays a key role in the development of primary diabetes and various diabetic complications" Link to NIH abstract. Full EPUB and PDF available.

Epilepsy

1. Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., … Friedman, D. (2014). Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791–802. http://doi.org/10.1111/epi.12631."CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction and neonatal hypoxic-ischemic encephalopathy." Link to NIH abstract. Full EPUB and PDF also available.
2. Filloux, F. M. (2015). Cannabinoids for pediatric epilepsy? Up in smoke or real science? Translational Pediatrics, 4(4), 271–282. http://doi.org/10.3978/j.issn.2224-4336.2015.10.03. "At present, high quality medical evidence supporting the use of these agents in most of these conditions remains modest at best." Link to NIH abstract. Full EPUB and PDF available.
3. Porter, B. E., & Jacobson, C. (2013). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior : E&B, 29(3), 574–577. http://doi.org/10.1016/j.yebeh.2013.08.037. "Sixteen (84%) of the 19 parents reported a reduction in their child’s seizure frequency while taking cannabidiol-enriched cannabis." Link to NIH abstract. Full EPUB and PDF available.

Eye protection


Liver toxicity, helps

1. Vilela, L. R., Gomides, L. F., David, B. A., Antunes, M. M., Diniz, A. B., Moreira, F. de A., & Menezes, G. B. (2015). Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine. Mediators of Inflammation, 2015, 523418. http://doi.org/10.1155/2015/523418. Link to NIH abstract. Full EPUB and PDF also available.

Misc

1. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 2003;17(3):179-202. Review. PubMed PMID: 12617697. Link to NIH abstract.
2. Silveira, J. W., Issy, A. C., Castania, V. A., Salmon, C. E. G., Nogueira-Barbosa, M. H., Guimarães, F. S., … Bel, E. D. (2014). Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration. PLoS ONE, 9(12), e113161. http://doi.org/10.1371/journal.pone.0113161. Link to NIH abstract. Full EPUB and PDF also available.

Neurological and nervous system disorders

1. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci. 2007 Sep 5;27(36):9537-44. PubMed PMID: 17804615. "When combined with its ability to target the brain and its lack of toxic side effects, CBD may represent a promising new anti-prion drug. In N2asc+ and Rov9sc+ cells, the level of PrPres accumulation was drastically reduced in the presence of CBD as estimated by Western blot analysis." Link to abstract. Full study here. Keywords: CJD.
2. Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323–333. http://doi.org/10.1111/j.1365-2125.2012.04341.x. Link to NIH abstract. Full EPUB and PDF available.
3. Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., … Vogel, Z. (2011). Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. British Journal of Pharmacology, 163(7), 1507–1519. http://doi.org/10.1111/j.1476-5381.2011.01379.x. Link to NIH abstract. Full EPUB and PDF available.

Psychiatric disorders

1. Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1607), 3364–3378. http://doi.org/10.1098/rstb.2011.0389. "It is now clear that CBD has therapeutic potential over a wide range of non-psychiatric and psychiatric disorders such as anxiety, depression and psychosis." Link to Abstract at NIH. Full EPUB and PDF also available. 

NIH library search for CBD studies.